Why the study?
Does low-dose warfarin or a combination of enoxaparin and warfarin provide cost savings compared to enoxaparin alone for DVT/PE prophylaxis in patients post-THA?
Does low-dose warfarin or a combination of enoxaparin and warfarin provide cost savings compared to enoxaparin alone for DVT/PE prophylaxis in patients post-THA?
Low-dose warfarin, alone or in combination with a short course of enoxaparin, is more cost-effective than enoxaparin alone for 30-day DVT/PE prophylaxis after total hip arthroplasty.
May support low-dose warfarin for cost savings in post-THA prophylaxis; leaves open net benefit pending randomized data.
Guidelines for deep venous thrombosis (DVT) and pulmonary embolism (PE) prophylaxis have been developed for patients undergoing total hip arthroplasty (THA). Studies suggest that risk for developing these complications may exist for as long as 3 months following surgery. Cost-effectiveness analyses were performed on three pharmacoprophylaxis regimens administered over a 30-day period using literature-reported values for incidences of DVT and PE in patients postdischarge following THA. A cost savings of $21,466.89 will occur for each thromboembolic event avoided if low-dose warfarin daily is used routinely compared to enoxaparin 40 mg daily. Additionally, a cost savings of $18,618.10 is experienced if enoxaparin 40 mg daily for 4 days plus low-dose warfarin daily is administered versus enoxaparin 40 mg daily. Clinicians may choose to continue prophylaxis postdischarge with enoxaparin 40 mg daily for 4 days in combination with warfarin for 30 days in these patients until results of more definitive studies become available.
No takes yet. Share an insight, caveat, or question.
Wade et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: